Impact of nucleosides analogues and nucleotide analogues on the outcomes related to chronic hepatitis B based on non-antiviral effects
10.3760/cma.j.cn501113-20221231-00616
- VernacularTitle:核苷类似物与核苷酸类似物基于非抗病毒作用对慢性乙型肝炎相关结局的影响
- Author:
Yuanqin DUAN
1
;
Zhiwei CHEN
;
Hong REN
;
Peng HU
Author Information
1. 重庆医科大学病毒性肝炎研究所 感染性疾病分子生物学教育部重点实验室 重庆医科大学附属第二医院感染科，重庆 400010
- Keywords:
Chronic hepatitis B;
Nucleotide analogue;
Tenofovir;
Entecavir
- From:
Chinese Journal of Hepatology
2023;31(8):880-885
- CountryChina
- Language:Chinese
-
Abstract:
Nucleoside analogues and nucleotide analogues can not only achieve long-term viral suppression in the treatment of most CHB patients but also have a positive impact on other CHB therapeutic goals and an improved prognosis. A certain difference can be observed in the impact of nucleotide analogues such as TDF and TAF and nucleoside analogues such as ETV on the clinical outcomes of CHB. Studies on the mechanism of action indicate that apart from inhibiting the direct antiviral effects of HBV reverse transcriptase, these two categories of drugs exhibit distinct impacts on immune-related signaling pathways, gene expression, genome stability, and other non-antiviral mechanisms. This article reviews the evidence on the potential non-antiviral mechanism of action of nucleoside analogues and nucleotide analogues and proposes a preliminary explanation for the observation trend of nucleotide analogues having a comparative advantage in clinical outcomes in CHB patients based on the latest research advancement.
